GSK - GlaxoSmithKline plc

NYSE - Nasdaq Real Time Price. Currency in USD
41.92
+0.44 (+1.07%)
As of 3:59PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close41.48
Open41.79
Bid41.94 x 1200
Ask41.95 x 3200
Day's Range41.73 - 42.38
52 Week Range38.43 - 48.25
Volume2,832,684
Avg. Volume3,133,685
Market Cap107.021B
Beta (5Y Monthly)0.34
PE Ratio (TTM)42.26
EPS (TTM)0.99
Earnings DateJan 31, 2017 - Feb 05, 2017
Forward Dividend & Yield2.40 (5.78%)
Ex-Dividend DateFeb 19, 2020
1y Target Est50.00
  • Investing in Biotech Stocks the Right Way During an Epidemic
    GuruFocus.com

    Investing in Biotech Stocks the Right Way During an Epidemic

    A few factors need to be considered before betting on health care stocks Continue reading...

  • Sanofi Plans Spin-Off of API Unit Into a European Company
    Zacks

    Sanofi Plans Spin-Off of API Unit Into a European Company

    Sanofi (SNY) plans to combine its API commercial activities with six of its European API production sites and spin-off the same into an independent European API company.

  • Barrons.com

    Global Markets Are Experiencing a Big Selloff Because of Coronavirus. Everything to Know.

    The S&P 500 was sitting at an all-time high. Now, it’s experiencing its worst day in two years as the market reacts to the spread of coronavirus. Here’s Barron’s take on everything from oil prices to pharmaceutical stocks to the market as a whole.

  • MarketWatch

    GSK's stock falls after it announces new coronavirus vaccine partnership

    Shares of GlaxoSmithKline Plc fell 1.8% in premarket trading on Monday after the drugmaker said it plans to test its technology with Chinese biotech Clover Biopharmaceuticals's vaccine candidate for COVID-19. GSK's adjuvant technology aims to reduce the amount of vaccine per dose, which would, in theory, allow more doses to be produced. COVID-19 is a new coronavirus that was first identified in December in Wuhan, China. Since then, it has spread to 29 other countries, sickening more than 79,000 people and killing at least 2,622 people. There are currently no vaccines or approved therapeutics that can prevent or treat the infection caused by the virus. GSK's adjuvant technology is also being tested for a COVID-19 vaccine by the Coalition for Epidemic Preparedness Innovations, which is working with a number of companies to develop a vaccine for the virus. GSK's stock is up 5% over the past year, while the S&P 500 has gained 20%.

  • Barrons.com

    Big Pharma Is Pushing Harder on Coronavirus. GlaxoSmithKline Discloses Effort With Chinese Biotech.

    Barron’s reported in late January that the largest vaccine makers were not yet working on COVID-19 programs, yet as the epidemic has progressed, that seems to be changing.

  • Pfizer Stock Tumbled On Lackluster Earnings — Should You Add Shares?
    Investor's Business Daily

    Pfizer Stock Tumbled On Lackluster Earnings — Should You Add Shares?

    Pfizer stock is on a recent downswing in the wake of lackluster fourth-quarter earnings. But shares are consolidating on the weekly chart. Is the pharmaceutical company a buy right now?

  • Reuters

    Pharmaceutical companies develop system to better track counterfeit drugs

    Some of the industry's largest pharmaceutical companies, including Pfizer Inc and Eli Lilly and Co, have developed a blockchain-based system to track prescription drugs across the supply chain to better halt the flow of counterfeit medicines, company officials said on Friday. Some two dozen companies in the industry including drugmakers, distributers, retailers and delivery firms created the blockchain-based MediLedger Network, which it has been testing in the verification of drug returns. Blockchain, which first emerged as the technology underlying virtual currency bitcoin, is a shared database maintained by a network of computers.

  • These are the steps needed for a vaccine to be approved
    MarketWatch

    These are the steps needed for a vaccine to be approved

    Thirty countries and territories have confirmed cases of the illness, called COVID-19; despite the containment measures in place, the number is still on the rise, seemingly unfettered. As the outbreak claims more lives and the number of infected continues to grow, pharmaceutical companies, governments, universities and the World Health Organization are working around the clock to develop a vaccine. Once it is eventually developed, tested and administered, a vaccine will enable an individual’s immune system to effectively respond to the viral infection, preventing its propagation among the inoculated.

  • Reuters

    UK PM Johnson reviewing government's engagement with business

    British Prime Minister Boris Johnson and his team are reviewing how best to engage with business, his office said on Thursday, after Sky News reported officials were keen to scrap the government's business advice councils. Sky reported Johnson was looking at overhauling five business councils set up in November 2018 by his predecessor Theresa May and that the existing structure was likely to be axed. Johnson has met the co-chairs of the business councils, who include Tesco boss Dave Lewis, BAE Systems Chairman Roger Carr and GlaxoSmithKline Chief Executive Emma Walmsley, only once since he took office in July.

  • The Zacks Analyst Blog Highlights: Facebook, Netflix, NextEra Energy, GlaxoSmithKline and T-Mobile US
    Zacks

    The Zacks Analyst Blog Highlights: Facebook, Netflix, NextEra Energy, GlaxoSmithKline and T-Mobile US

    The Zacks Analyst Blog Highlights: Facebook, Netflix, NextEra Energy, GlaxoSmithKline and T-Mobile US

  • Top Research Reports for Facebook, Netflix & NextEra Energy
    Zacks

    Top Research Reports for Facebook, Netflix & NextEra Energy

    Top Research Reports for Facebook, Netflix & NextEra Energy

  • China’s tourism, automotive industries sink amid COVID-19 outbreak
    MarketWatch

    China’s tourism, automotive industries sink amid COVID-19 outbreak

    China’s extraordinary economic growth over the past four decades transformed the country into the world’s second-biggest economy. The key to this growth is global trade. China is not only the largest trading partner in the world, but it is also central to a myriad of supply chains.

  • Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine
    Zacks

    Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine

    Sanofi (SNY) and J&J (JNJ) sign deals with BARDA, part of U.S. Department of Health and Human Services, for accelerated development of a vaccine for the newly found coronavirus.

  • Glaxo Underperforms Industry in a Year: What's in Store?
    Zacks

    Glaxo Underperforms Industry in a Year: What's in Store?

    Shares of Glaxo (GSK) lag the industry in a year as generic erosion of some drugs mainly its top-selling drug, Advair offsets strong sales of new drugs.

  • The Triangle's big slice of NC bio/pharma pie – List Insights
    American City Business Journals

    The Triangle's big slice of NC bio/pharma pie – List Insights

    The life sciences industry is no doubt big business in North Carolina with more than 735 bioscience companies and a total of more than 66,000 industry workers. And the Triangle has its fair share of that pie. Bio/pharma companies are the focus of one of this week’s Triangle Business Journal lists.

  • MoneyShow

    Global Drug Stocks with a Prescription for Income

    Income investors can leverage the increased demand for healthcare into strong total returns, explains Ned Piplovic, editor of DividendInvestor. Here, he reviews two global pharmaceutical firms that are attractive for investors seeking both growth and income.

  • PR Newswire

    FDA approves GSK's Voltaren Arthritis Pain for over-the-counter use in the United States

    GlaxoSmithKline (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID)- arthritis pain reliever) as an over-the-counter (OTC) product for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults (18 years and older). With the FDA's approval, Voltaren Arthritis Pain becomes the first and only prescription strength, nonsteroidal anti-inflammatory (NSAID) topical gel for arthritis pain available OTC in the United States.

  • Reuters

    Indian generic drugmakers may see supply shortages from China if coronavirus drags on

    Shortages and potential price increases of generic drugs from India loom if the coronavirus outbreak disrupts suppliers of pharmaceutical ingredients in China past April, according to industry experts. An important supplier of generic drugs to the world, Indian companies procure almost 70% of the active pharmaceutical ingredients (APIs) for their medicines from China. India's generic drugmakers say they currently have enough API supplies from China to cover their operations for up to about three months.

  • Coronavirus update: 1,018 deaths, a new case in San Diego, 195 evacuees expected to leave quarantine
    MarketWatch

    Coronavirus update: 1,018 deaths, a new case in San Diego, 195 evacuees expected to leave quarantine

    A passenger who was repatriated from Wuhan, China, on a U.S. flight and has been in quarantine in San Diego is the latest individual in the U.S. to test positive for the coronavirus, according to media reports.

  • Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance
    Zacks

    Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance

    The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.

  • GlaxoSmithKline plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
    Simply Wall St.

    GlaxoSmithKline plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

    GlaxoSmithKline plc (LON:GSK) shares fell 4.7% to UK£17.00 in the week since its latest yearly results. The result was...

  • Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales
    Zacks

    Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales

    Seattle Genetics (SGEN) rides high on Q4 earnings and revenue beat.

  • Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split
    Zacks

    Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

    Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.

  • Can Biotech ETFs Continue to Soar in 2020?
    Zacks

    Can Biotech ETFs Continue to Soar in 2020?

    We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.